Attached files

file filename
EX-3.1B - EXHIBIT 3.1B - Anika Therapeutics, Inc.exh_31b.htm
EX-3.1E - EXHIBIT 3.1E - Anika Therapeutics, Inc.exh_31e.htm
EX-3.1C - EXHIBIT 3.1C - Anika Therapeutics, Inc.exh_31c.htm
EX-3.1A - EXHIBIT 3.1A - Anika Therapeutics, Inc.exh_31a.htm
EX-31.2 - EXHIBIT 31.2 - Anika Therapeutics, Inc.exh_312.htm
EX-32.1 - EXHIBIT 32.1 - Anika Therapeutics, Inc.exh_321.htm
EX-31.1 - EXHIBIT 31.1 - Anika Therapeutics, Inc.exh_311.htm
EX-21.1 - EXHIBIT 21.1 - Anika Therapeutics, Inc.exh_211.htm
EX-10.16 - EXHIBIT 10.16 - Anika Therapeutics, Inc.exh_1016.htm
EX-10.17 - EXHIBIT 10.17 - Anika Therapeutics, Inc.exh_1017.htm
EXCEL - IDEA: XBRL DOCUMENT - Anika Therapeutics, Inc.Financial_Report.xls
10-K - FORM 10-K - Anika Therapeutics, Inc.f10k_031215.htm
EXHIBIT 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos.  333-06275, 333-66831, 333-79047, 333-58264, 333-110326, 333-160102, 333-176103 and 333-190597) of Anika Therapeutics, Inc. of our report dated March 13, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
 
Boston, Massachusetts
March 13, 2015